Clinical trials: Allogeneic Disease
Crohn's Disease
Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders
This project aims to assess safety and efficacy of allogeneic Mesenchymal stem Cell (MSC) in Crohn's disease refractory or intolerant to conventional therapies.
- Trial name
- NCT01540292
- Testing
- Mesenchymal Stem Cells (MSC)
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- University of Liege
Multiple Myeloma, Allogeneic Stem Cell Transplantation
Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant
Most patients with multiple myeloma (MM) die due to relapse resistant to current treatment, including treatment with anti-B cell maturation antigen (BCMA) CAR-T cells.
- Trial name
- CARTemis-1 (NCT05982275)
- Testing
- CARTemis-1
- Where
- 5 sites in Spain
- Volunteers
- 25 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Chronic Lymphocytic Leukemia, Richter's Transformation
Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation
The primary objective of the study is to evaluate the feasibility, efficacy and safety of an obinutuzumab containing conditioning regimen for poor risk CLL patients and patients with Richter's transformation requiring an…
- Trial name
- CLLTX1 (NCT03153514)
- Testing
- Obinutuzumab
- Where
- 7 sites in Germany
- Volunteers
- 3 people
- Sponsor
- German CLL Study Group
Acute Myeloblastic Leukemia, Lymphoblastic Leukemia
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
The purpose of this study is to compare Reduced Intensity Conditioning protocols containing either Thymoglobuline or Alemtuzumab in patients undergoing allogeneic transplant from voluntary unrelated donors.
- Conditions
- Acute Myeloblastic Leukemia, Lymphoblastic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
- Trial name
- GLOBAL (NCT00354120)
- Testing
- Alentuzumab, Globulina antilinfocitaria
- Where
- 22 sites in Italy
- Volunteers
- 121 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Steroid Refractory GVHD
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Steroid-refractory graft-vs-host disease (SR-GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT05663827
- Testing
- Ruxolitinib
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Yi-Lun Wang
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
Chronic Graft Versus Host Disease (GVHD) is one of the most challenging complications in long term survivors of allogeneic stem cell transplantation.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT03066466
- Testing
- Atorvastatin, Methotrexate, Tacrolimus
- Where
- United States
- Sponsor
- Loyola University
Chronic Back Pain, Degenerative Disc Disease Lumbar
CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
CELZ-201-DDT is an investigational (experimental) cell therapy currently being studied for people with degenerative disc disease who have chronic lower back pain.
- Trial name
- ADAPT (NCT07137559)
- Testing
- CELZ-201-DDT
- Sponsor
- Creative Medical Technology Holdings Inc
Critical Limb Ischemia
Mesenchymal Stem Cells in Critical Limb Ischemia
This clinical trial aims to study the safety and efficacy of adult mesenchymal stem cells in critical limb ischemia.
- Trial name
- NCT00883870
- Testing
- mesenchymal stem cells, Plasmalyte A
- Where
- 4 sites in India
- Volunteers
- 20 people
- Sponsor
- Stempeutics Research Pvt Ltd
Knee Osteoarthritis
Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis
Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy
- Trial name
- NCT04208646
- Testing
- Mesenchymal progenitor cells, No mesenchymal progenitor cells
- Where
- 7 sites in China
- Volunteers
- 106 people
- Sponsor
- Shanghai AbelZeta Ltd.
Respiratory Distress Syndrome, Adult
Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)
This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in…
- Trial name
- START (NCT02097641)
- Testing
- Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Michael A. Matthay
Acute Myeloid Leukemia, Adult, Graft Versus Host Disease
Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
The investigators aimed to reveal the relationship between serum markers of pyroptosis, GVHD biomarkers and endothelial damage markers in patients who were planned for allogeneic stem cell transplantation for AML and developed…
- Conditions
- Acute Myeloid Leukemia, Adult, Graft Versus Host Disease, Endothelial Dysfunction
- Trial name
- NCT06200441
- Where
- Turkey (Türkiye)
- Sponsor
- Ugur Arzu Kulu
Pneumonia, Idiopathic Pneumonia Syndrome
Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)
The study is designed as a Phase III, multi-center randomized, double-blind, placebo-controlled trial investigating the use of etanercept for the treatment of acute, non-infectious pulmonary dysfunction (IPS) occurring after…
- Trial name
- NCT00421174
- Testing
- Etanercept
- Where
- 12 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multiple Myeloma
CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma
1. Study Title CAR-T Cell Therapy Combined with Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma 2.
- Trial name
- CAR-T-allo (NCT06913179)
- Testing
- All enrolled patients will first receive CAR-T cell therapy. Patients who achieve complete remission following CAR-T infusion will subsequently undergo allo-HSCT
- Volunteers
- 30 people
- Sponsor
- Xuzhou Medical University
Graft Versus Host Disease in GI Tract
Fecal Microbiota Transplantation in aGvHD After ASCT
Acute graft-versus-host-disease (aGvHD) is a typical complication after allogeneic hematopoetic stem cell transplantation (ASCT).
- Trial name
- NCT03819803
- Testing
- Fecal microbiota transplantation
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Medical University of Graz
Graft vs Host Disease
Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease
Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa possesses potent anti-inflammatory and immunosuppressive properties.
- Trial name
- NCT02478424
- Testing
- Cannabidiol, cyclosporine, Methotrexate
- Volunteers
- 10 people
- Sponsor
- Rabin Medical Center
Amyotrophic Lateral Sclerosis
Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS
The purpose of this study is to evaluate the safety and efficacy of HLA-haplo matched Allogenic Bone Marrow Derived stem cells("HYNRCS-Allo-ALS-02 inj"), through intrathecal delivery for the repeated treatment after 6 months of…
- Trial name
- NCT03214146
- Testing
- HYNRCS-Allo inj
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Hanyang University Seoul Hospital
Cardiotoxicity, DPP3
Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year.
- Conditions
- Cardiotoxicity, DPP3, HSCT, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- ALLOCARDIOTOX (NCT07157670)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hidradenitis Suppurativa
Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa
Multicenter Phase I/II Clinical Trial to Evaluate Safety and Efficiency of Allogenic Adult Mesenchymal Stem Cell from Adipose Tissue in Patients With Hidradenitis Suppurativa
- Trial name
- NCT05934825
- Testing
- Injectable suspension of allogeneic adult mesenchymal stem cells
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Andalusian Network for Design and Translation of Advanced Therapies
Platelet Disorder
Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant
This phase II trial studies the side effects and how well avatrombopag works for the treatment of thrombocytopenia after donor hematopoietic stem cell transplant.
- Trial name
- NCT04312789
- Testing
- Avatrombopag
- Sponsor
- Ayman Saad
Acute Myeloid Leukemia
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Elderly patients with acute myeloid leukemia (AML) often face unfavorable prognostic factors such as multiple comorbidities, adverse cytogenetic profiles, and pre-existing hematological disorders.
- Trial name
- NCT06571825
- Testing
- Venetoclax, Allogeneic transplant
- Where
- China
- Volunteers
- 118 people
- Sponsor
- He Huang